Trial · NCT04667104
Adverse events78
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 78
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Leukopenia | Blood and lymphatic system disorders | TP 1:JNJ-73763989 200 mg+JNJ-56136379 250 mg+NA | 0 | 48 | 0 |
| other | Leukopenia | Blood and lymphatic system disorders | TP 2:JNJ-3989 200 mg+JNJ-6379 250 mg+PegIFN-alpha2a 180 mcg+NA | 3 | 48 | 4 |
| other | Leukopenia | Blood and lymphatic system disorders | Follow-Up (FU) Period-nucleos(t)Ide Analog (NA) | 0 | 48 | 0 |
| other | Neutropenia | Blood and lymphatic system disorders | TP 1:JNJ-73763989 200 mg+JNJ-56136379 250 mg+NA | 0 | 48 | 0 |
| other | Neutropenia | Blood and lymphatic system disorders | TP 2:JNJ-3989 200 mg+JNJ-6379 250 mg+PegIFN-alpha2a 180 mcg+NA | 4 | 48 | 6 |
| other | Neutropenia | Blood and lymphatic system disorders | Follow-Up (FU) Period-nucleos(t)Ide Analog (NA) | 0 | 48 | 0 |
| other | Thrombocytopenia | Blood and lymphatic system disorders | TP 1:JNJ-73763989 200 mg+JNJ-56136379 250 mg+NA | 0 | 48 | 0 |
| other | Thrombocytopenia | Blood and lymphatic system disorders | TP 2:JNJ-3989 200 mg+JNJ-6379 250 mg+PegIFN-alpha2a 180 mcg+NA | 4 | 48 | 5 |
| other | Thrombocytopenia | Blood and lymphatic system disorders | Follow-Up (FU) Period-nucleos(t)Ide Analog (NA) | 1 | 48 | 1 |
| other | Diarrhoea | Gastrointestinal disorders | TP 1:JNJ-73763989 200 mg+JNJ-56136379 250 mg+NA | 0 | 48 | 0 |
| other | Diarrhoea | Gastrointestinal disorders | TP 2:JNJ-3989 200 mg+JNJ-6379 250 mg+PegIFN-alpha2a 180 mcg+NA | 3 | 48 | 3 |
| other | Diarrhoea | Gastrointestinal disorders | Follow-Up (FU) Period-nucleos(t)Ide Analog (NA) | 0 | 48 | 0 |
| other | Fatigue | General disorders | TP 1:JNJ-73763989 200 mg+JNJ-56136379 250 mg+NA | 3 | 48 | 3 |
| other | Fatigue | General disorders | TP 2:JNJ-3989 200 mg+JNJ-6379 250 mg+PegIFN-alpha2a 180 mcg+NA | 5 | 48 | 5 |
| other | Fatigue | General disorders | Follow-Up (FU) Period-nucleos(t)Ide Analog (NA) | 1 | 48 | 1 |
| other | Influenza Like Illness | General disorders | TP 1:JNJ-73763989 200 mg+JNJ-56136379 250 mg+NA | 0 | 48 | 0 |
| other | Influenza Like Illness | General disorders | TP 2:JNJ-3989 200 mg+JNJ-6379 250 mg+PegIFN-alpha2a 180 mcg+NA | 6 | 48 | 7 |
| other | Influenza Like Illness | General disorders | Follow-Up (FU) Period-nucleos(t)Ide Analog (NA) | 0 | 48 | 0 |
| other | Injection Site Erythema | General disorders | TP 1:JNJ-73763989 200 mg+JNJ-56136379 250 mg+NA | 1 | 48 | 1 |
| other | Injection Site Erythema | General disorders | TP 2:JNJ-3989 200 mg+JNJ-6379 250 mg+PegIFN-alpha2a 180 mcg+NA | 7 | 48 | 10 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04667104/events